Annals of Indian Academy of Neurology (Jan 2022)

Impact of COVID-19 on guillain-barre syndrome in India: A multicenter ambispective cohort study

  • Yareeda Sireesha,
  • Ritu Shree,
  • Madhu Nagappa,
  • Anuja Patil,
  • Monika Singla,
  • M V Padma Srivastava,
  • R K Dhamija,
  • Neetha Balaram,
  • Abhishek Pathak,
  • Dileep Ramachandran,
  • Sujit Kumar,
  • Inder Puri,
  • Sudhir Sharma,
  • Samhita Panda,
  • Soaham Desai,
  • Priyanka Samal,
  • Aditya Choudhary,
  • Pamidimukkala Vijaya,
  • Teresa Ferreira,
  • S S Nair,
  • H P Sinha,
  • S K Bhoi,
  • Joseph Sebastian,
  • Sanjay Sharma,
  • Aneesh Basheer,
  • Manish Bhartiya,
  • N L Mathukumalli,
  • Shaikh Afshan Jabeen,
  • Vivek Lal,
  • Manish Modi,
  • P Praveen Sharma,
  • Subash Kaul,
  • Gagandeep Singh,
  • Ayush Agarwal,
  • Divyani Garg,
  • James Jose,
  • Priya Dev,
  • Thomas Iype,
  • Maya Gopalakrishnan,
  • Ashish Upadhyay,
  • Rohit Bhatia,
  • Awadh K Pandit,
  • Rajesh K Singh,
  • Manish Salunkhe,
  • P M Yogeesh,
  • Alisha Reyaz,
  • Nishant Nadda,
  • Menkha Jha,
  • Bismay Kumar,
  • P K Kushwaha,
  • Harshadkumar Chovatiya,
  • Bhavani Madduluri,
  • P Ramesh,
  • Abeer Goel,
  • Rahul Yadav,
  • Venugopalan Y Vishnu

DOI
https://doi.org/10.4103/aian.aian_523_22
Journal volume & issue
Vol. 25, no. 6
pp. 1116 – 1121

Abstract

Read online

Introduction/Aims: Studies conducted during the coronavirus disease 2019 (COVID-19) pandemic have reported varied data regarding the incidence of Guillain–Barre syndrome (GBS). The present study investigated demographic and clinical features, management, and outcomes of patients with GBS during a specified period of the COVID-19 pandemic, and compared these features to those of GBS in the previous year. Methods: A multicenter, ambispective cohort study including 26 centers across India was conducted. Data from a pre-COVID-19 period (March 1 to August 31, 2019) were collected retrospectively and collected ambispectively for a specified COVID-19 period (March 1 to August 31, 2020). The study was registered with the Clinical Trial Registry India (CTRI/2020/11/029143). Results: Data from 555 patients were included for analysis: pre-COVID-19 (n = 334) and COVID-19 (n = 221). Males were more commonly affected during both periods (male:female, 2:1). Gastroenteritis was the most frequent antecedent event in 2019 (17.4%), whereas fever was the most common event in 2020 (10.7%). Paraparesis (21.3% versus [vs.] 9.3%, P = 0.001) and sensory involvement (51.1% vs. 41.3%; P = 0.023) were more common during COVID-19 in 2020, whereas back pain (26.3% vs. 18.4%; P = 0.032) and bowel symptoms (20.7% vs. 13.7%; P = 0.024) were more frequent in the pre-COVID period. There was no difference in clinical outcomes between the two groups in terms of GBS disability score at discharge and 3 months after discharge. Independent predictors of disability in the pre-COVID period included areflexia/hyporeflexia, the requirementfor intubation, and time to bulbar weakness; in the COVID-19 period, independent predictors included time from onset to admission, intubation, and intubation requirement. The mortality rate was 2.3% during the entire study period (13/555 cases). Discussion: Results of this study revealed an overall reduction in the frequency of GBS during the pandemic. The lockdown likely reduced the risk for antecedent infections due to social distancing and improved hygiene, which may have resulted in the reduction of the frequency of GBS.

Keywords